Back to top
more

Fulcrum Therapeutics (FULC)

(Real Time Quote from BATS)

$7.13 USD

7.13
36,024

-0.01 (-0.14%)

Updated Apr 29, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for FULC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Fulcrum Therapeutics, Inc. [FULC]

Reports for Purchase

Showing records 1 - 20 ( 31 total )

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/28/2024

Company Report

Pages: 7

Fulcrum Looks to "REACH" New Heights in 2024: Reit. Buy and Modulating our PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/08/2023

Company Report

Pages: 7

Fulcrum’s Pipeline Looks For Balance Heading into 2024; Reit. Buy and $14 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/23/2023

Company Report

Pages: 7

The Removal of ‘6058’s Clinical Hold Lights a Clearer Pathway to SCD; Upgrading to Buy and $14 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/04/2023

Company Report

Pages: 7

Revisiting The Potential of REACH, as FHTX-6058’s Future Remains Unclear; Reit. Neutral and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/16/2023

Company Report

Pages: 7

Hematologic Malignancy FDA Hold Remains a Difficult Hurdle; Reit. Neutral and Modulating PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/10/2023

Company Report

Pages: 7

Unclear If Hematologic Malignancies Stem From A Class Effect or Compound; Downgrading to Neutral; PT Down To $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/27/2023

Daily Note

Pages: 5

Curious Clinical Hold, Impacts FTX-6058 Development in SCD; Reiterate Buy and $20 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/09/2022

Company Report

Pages: 7

Progress From FTX-6058 and Losmapimod Shape Long/Short-Term Thesis; Reit. Buy and $20 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

08/12/2022

Company Report

Pages: 7

Fulcrum Doubles Down on FTX-6058 and Losmapimod; Reit Buy and $20 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/10/2022

Company Report

Pages: 7

Initial FTX-6058 Data in SCD, Likely to Be Met With a Polarizing Reaction

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/10/2022

Company Report

Pages: 7

Bullish Ahead of FTX-6058 Data at EHA; Reit. Buy and $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/25/2022

Daily Note

Pages: 4

Fulcrum’s FSHD KOL Event Sheds Light on RWS as a Viable Primary Endpoint

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/22/2022

Company Report

Pages: 4

KOLs Are Optimistic on REACH Study, But Highlight Many Unknowns in FSHD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/04/2022

Company Report

Pages: 7

Phase 3 REACH Initiating in 2Q22 Along with FTX-6058 Phase 1b Data; Reit. Buy, $40 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/06/2021

Daily Note

Pages: 4

FTX-6058 Continues to Impress at Higher Doses, Increasing Hopes For Efficacy in SCD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/05/2021

Company Report

Pages: 7

FTX-6058 Continues to Generate Interest, Update Expected by YE21; Reit Buy and $40PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for FULC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/17/2021

Company Report

Pages: 8

FTX-6058 Exceeds Investor Expectations; Reit Buy and Raising Our PT to $40 from $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/10/2021

Daily Note

Pages: 4

Positive FTX-6058 Phase 1 Data Further De-risks EED Targeting in SCD.

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Fulcrum Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/25/2021

Daily Note

Pages: 6

ReDUX4 Misses Primary Endpoint, Though Clinical Benefit Seen Across Secondary Endpoints

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party